CROX
Crocs, Inc.
CROX has the edge over TSLA overall, supported by stronger fundamentals and stronger valuation.
TSLA
Tesla, Inc.
TSLA's outlook is improving, though it still trails on the overall score.
CROX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Strong |
CROX's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
TSLA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Strong |
TSLA's revenue and balance sheet are currently healthy, and its profitability is stable, but its cash flow is under pressure.
CROX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.4x | $97.23 | -38% |
| Forward | 9.9x | $157 | — |
| Fair | 11x | $146 | -7.1% |
| Current | 12x | $157 | — |
| Expensive | 22x | $286 | +82% |
Historical ranges are pointers, not guarantees.
CROX has the edge over TSLA in the historical PE scenario, which offers more potential upside but is not a forecast.
TSLA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 60x | $54.70 | -86% |
| Fair | 174x | $158 | -60% |
| Forward | 196x | $397 | — |
| Expensive | 415x | $378 | -4.9% |
| Current | 437x | $397 | — |
Historical ranges are pointers, not guarantees.
TSLA's PE is in its expensive range at 437x. If earnings grow as analysts expect, today's price would be 196x next year's earnings, in its fair range.
CROX Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
CROX has the edge over TSLA on the outlook, with more favorable profitability expectations.
TSLA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for TSLA, with profitability holding steady. However, they disagree widely on these estimates.
CROX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $15.91 | +21% |
| Q3 2026 | $13.15 | +344% |
| Q2 2026 | $11.33 | +213% |
| Q1 2026 | -$1.62 | -110% |
| Q4 2025 | -$1.50 | -109% |
| Q3 2025 | $2.96 | -79% |
| Q2 2025 | $3.62 | -73% |
| Q1 2025 | $16.21 | +26% |
| Q4 2024 | $15.88 | +24% |
CROX has the edge over TSLA on earnings, with more consistent year-over-year improvement.
TSLA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.03 | +123% |
| Q3 2026 | $0.91 | -39% |
| Q2 2026 | $1.08 | -38% |
| Q1 2026 | $1.09 | -40% |
| Q4 2025 | $1.08 | -47% |
| Q3 2025 | $1.50 | -59% |
| Q2 2025 | $1.73 | -51% |
| Q1 2025 | $1.82 | -53% |
| Q4 2024 | $2.04 | -53% |
TSLA's earnings per share have fallen from their peak: $0.91 over the past year, against $4.30 in late 2023.
CROX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1B | +4.6% |
| Q2 2026 | $1.2B | +2.6% |
| Q1 2026 | $921.5M | -1.7% |
| Q4 2025 | $957.6M | -3.2% |
| Q3 2025 | $996.3M | -6.2% |
| Q2 2025 | $1.1B | +3.4% |
| Q1 2025 | $937.3M | -0.1% |
| Q4 2024 | $989.8M | +3.1% |
CROX has the edge over TSLA on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 28% | +7.2 points |
| Q2 2026 | 24% | +61 points |
| Q1 2026 | 22% | -2 points |
| Q4 2025 | 15% | -4.9 points |
| Q3 2025 | 21% | -4.6 points |
| Q2 2025 | -37% | -67 points |
| Q1 2025 | 24% | -0.3 points |
| Q4 2024 | 20% | -1.6 points |
CROX has the edge over TSLA on profitability, with a higher operating margin.
TSLA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $28B | -0.2% |
| Q2 2026 | $28.2B | +26% |
| Q1 2026 | $22.4B | +16% |
| Q4 2025 | $24.9B | -3.1% |
| Q3 2025 | $28.1B | +12% |
| Q2 2025 | $22.5B | -12% |
| Q1 2025 | $19.3B | -9.2% |
| Q4 2024 | $25.7B | +2.1% |
TSLA's revenue has picked up after two years of holding roughly level: $28B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 2.6% | -3.2 points |
| Q2 2026 | 1.4% | -2.7 points |
| Q1 2026 | 4.2% | +2.1 points |
| Q4 2025 | 5.7% | -0.5 points |
| Q3 2025 | 5.8% | -5 points |
| Q2 2025 | 4.1% | -2.2 points |
| Q1 2025 | 2.1% | -3.4 points |
| Q4 2024 | 6.2% | -2 points |
TSLA's operating margin was 2.6% last quarter, down 3.2 points from the same quarter a year ago, near the bottom of its range since 2019.
CROX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $275.5M | +22% |
| Q2 2026 | $331M | +23% |
| Q1 2026 | -$98.9M | -$16.3M |
| Q4 2025 | $246.4M | -19% |
| Q3 2025 | $226.2M | -19% |
| Q2 2025 | $269.2M | -30% |
| Q1 2025 | -$82.6M | -$39.3M |
| Q4 2024 | $303.4M | -5.3% |
CROX generated $754M in free cash flow over the past year, up 5.3% from the year before.
TSLA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.5B | -62% |
| Q2 2026 | -$1.1B | -848% |
| Q1 2026 | $1.4B | +117% |
| Q4 2025 | $1.4B | -30% |
| Q3 2025 | $4B | +46% |
| Q2 2025 | $146M | -89% |
| Q1 2025 | $664M | +$3.2B |
| Q4 2024 | $2B | -1.6% |
TSLA has the edge over CROX on cash flow, with more consistent year-over-year improvement.
CROX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.4% | -1.7M shares |
| 1 year | -11% | -6M shares |
| 3 years | -22% | -13.7M shares |
| 5 years | -24% | -15.4M shares |
| Available history | -33% | -23.8M shares |
CROX has the edge over TSLA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $250M |
| Q2 2026 | $256.2M |
| Q1 2026 | — |
| Q4 2025 | $180.2M |
| Q3 2025 | $208M |
| Q2 2025 | $133.3M |
| Q1 2025 | $60.9M |
| Q4 2024 | $226.3M |
CROX spent $686M buying back its own shares over the past year, up 9.2% from the year before.
TSLA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +1M shares |
| 1 year | +0.4% | +15M shares |
| 3 years | +1.4% | +48M shares |
| 5 years | +5.1% | +172M shares |
| Available history | +33% | +886M shares |
TSLA has 3.5B diluted shares, about the same as a year ago.
CROX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.1x | Healthy |
| Q2 2026 | 1.2x | Healthy |
| Q1 2026 | 5.8x | High |
| Q4 2025 | 4.8x | High |
| Q3 2025 | 4.2x | High |
| Q2 2025 | 3.5x | Elevated |
| Q1 2025 | 1.2x | Healthy |
| Q4 2024 | 1.1x | Healthy |
CROX's net debt is about 1.1 years of its operating earnings (EBITDA), down from 4.2 years a year ago.
TSLA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.1x | Net Cash |
| Q2 2026 | -0.8x | Net Cash |
| Q1 2026 | -0.9x | Net Cash |
| Q4 2025 | -1.1x | Net Cash |
| Q3 2025 | -1.4x | Net Cash |
| Q2 2025 | -1.1x | Net Cash |
| Q1 2025 | -1.1x | Net Cash |
| Q4 2024 | -1.0x | Net Cash |
TSLA has the edge over CROX on leverage, with a lower net debt burden relative to earnings.
CROX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.6 | Neutral |
| Stochastic | 88.0 | Overbought |
CROX's weekly RSI is 69 (neutral) and its Stochastic is 88 (overbought).
TSLA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.3 | Neutral |
| Stochastic | 72.6 | Neutral |
TSLA's weekly RSI is 54 (neutral) and its Stochastic is 73 (neutral).
CROX PE vs Consumer Cyclical Sector
| Metric | CROX | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 18x | 34% below |
| PE % | 57 | 47 | 10 pts above |
CROX has the edge over TSLA on valuation relative to its sector.
TSLA PE vs Consumer Cyclical Sector
| Metric | TSLA | Sector median | Relative |
|---|---|---|---|
| PE | 437x | 18x | 2,324% above |
| PE % | 84 | 47 | 37 pts above |
TSLA is trading at 437x earnings, a 2324% premium to the Consumer Cyclical sector's median of 18x.
CROX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $132.6 | 18% above |
| 20 week MA | $129.2 | 21% above |
| 50 week MA | $109.7 | 43% above |
| 100 week MA | $102.8 | 53% above |
| 200 week MA | $110.2 | 42% above |
CROX has climbed back above all five of its weekly moving averages, and it's now 42% above its 200-week average.
TSLA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $376.0 | 5.7% above |
| 20 week MA | $364.0 | 9.2% above |
| 50 week MA | $393.6 | 1% above |
| 100 week MA | $372.1 | 6.8% above |
| 200 week MA | $296.9 | 34% above |
TSLA is in an uptrend: it's above all five of its weekly moving averages, and 34% above its 200-week average.
CROX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $41.3 | $62.7 | +52% |
| 2021 | $62.7 | $123.5 | +97% |
| 2022 | $123.5 | $103.0 | -17% |
| 2023 | $103.0 | $93.4 | -9.3% |
| 2024 | $93.4 | $110.7 | +19% |
| 2025 | $110.7 | $91.6 | -17% |
| 2026 YTD | $91.6 | $156.9 | +71% |
CROX has the edge over TSLA on returns for 2026, with the stronger performance.
TSLA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $28.7 | $220.6 | +669% |
| 2021 | $220.6 | $355.7 | +61% |
| 2022 | $355.7 | $123.2 | -65% |
| 2023 | $123.2 | $248.5 | +102% |
| 2024 | $248.5 | $431.7 | +74% |
| 2025 | $431.7 | $475.2 | +10% |
| 2026 YTD | $475.2 | $397.5 | -16% |
TSLA's yearly returns have swung widely, from +669% in 2020 to −65% in 2022. It's down 16% so far in 2026.